Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.

Assiut University

Status: Completed

Conditions: Coagulation Disorder

Treatments: Device: Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA

Study type: Observational

Funder types: Other

Identifiers

NCT04479280

17300446

Details and patient eligibility

About

Novel coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this pneumonia was first emerged in December 2019 in Wuhan, China and rapidly spread around the world .

Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation

Enrollment: 70 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• COVID 19 critically ill patients

Exclusion criteria

• any critical illness not related to COVID 19

Trial design

70 participants in 2 patient groups

Covid19 positive patients

Treatment:

Device: Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA

Covid19 negative patients

Treatment:

Device: Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA